sabcs 2017: immunotherapy shows early promise for patients with trastuzumab-resistant breast cancer
Published 6 years ago • 412 plays • Length 13:56Download video MP4
Download video MP3
Similar videos
-
9:00
immunotherapy shows early promise for patients with trastuzumab-resistant breast cancer
-
12:04
sabcs 2017: adjuvant trastuzumab did not improve outcomes for patients with her2-low breast cancer
-
4:27
study of immunotherapy combinations for patients with her2-positive metastatic breast cancer
-
6:17
sara tolaney, sabcs 2022: adjuvant paclitaxel and trastuzumab for node-negative her2 breast cancer
-
5:46
sabcs snippets: immunology in hormone receptor positive breast cancer
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
2:54
panacea trial and implications for pembrolizumab use in breast cancer
-
3:26
sabcs 2017 – irene wapnir, part 1
-
21:39
new research in metastatic breast cancer | sabcs 2019
-
23:43
sabcs 2014 - immunotherapy in breast cancer
-
2:16
sabcs 2022: destiny-breast02 destiny-breast03
-
1:00
aphinity update - pertuzumab in her2 breast cancer
-
16:44
phase iii katherine clinical trial
-
28:29
educational sessions: "immunotherapy in the metastatic setting - chemo backbone and biomarker"
-
16:10
dr. ian krop | san antonio breast cancer symposium 2022 | general session
-
16:51
dr. jan liefers gerrit | san antonio breast cancer symposium 2022 | general session
-
2:56
key clinical trials in breast cancer presented at sabcs 2021
-
27:47
dr. melinda telli | sa antonio breast cancer symposium 2022 | clinical research workshop